⚕ GalenOps field
←

SITE015-0044

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE015 (POL) · Dr. Ito
consented 2022-04-17

AEs
6
Serious
0
Dropout signal
–

Adverse events

moderate assessed

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-05-15 (study day 15); relationship: not assessed

mild assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-05-15 (study day 15); relationship: Y

moderate assessed

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-10-30 (study day 183); relationship: Y

mild assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-08-15 (study day 472); relationship: Y

moderate assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2024-01-23 (study day 633); relationship: not assessed

mild assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2024-04-13 (study day 714); relationship: not assessed

Data queries

No data queries.